Cara Therapeutics, Inc. (NASDAQ:CARA) to Post FY2028 Earnings of ($0.21) Per Share, HC Wainwright Forecasts

Cara Therapeutics, Inc. (NASDAQ:CARA) – Equities research analysts at HC Wainwright issued their FY2028 earnings per share estimates for Cara Therapeutics in a research report issued to clients and investors on Friday, April 12th. HC Wainwright analyst O. Livnat expects that the biopharmaceutical company will post earnings of ($0.21) per share for the year. HC Wainwright currently has a “Buy” rating and a $2.50 price target on the stock. The consensus estimate for Cara Therapeutics’ current full-year earnings is ($1.25) per share.

Cara Therapeutics (NASDAQ:CARA) last posted its earnings results on Monday, March 4th. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.02). The company had revenue of $3.00 million for the quarter, compared to analyst estimates of $2.34 million. Cara Therapeutics had a negative return on equity of 122.10% and a negative net margin of 565.21%. During the same quarter in the previous year, the firm posted ($0.56) earnings per share.

A number of other brokerages have also recently issued reports on CARA. Canaccord Genuity Group dropped their price objective on Cara Therapeutics from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, March 6th. Needham & Company LLC restated a “buy” rating and issued a $5.00 price target on shares of Cara Therapeutics in a research note on Wednesday, April 10th. Finally, StockNews.com cut Cara Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, March 6th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $9.75.

Cara Therapeutics Stock Performance

Shares of CARA opened at $0.71 on Monday. The firm has a market capitalization of $38.81 million, a PE ratio of -0.33 and a beta of 0.70. The stock has a 50 day simple moving average of $0.81 and a 200 day simple moving average of $0.93. Cara Therapeutics has a 52-week low of $0.50 and a 52-week high of $4.67.

Institutional Trading of Cara Therapeutics

Hedge funds have recently made changes to their positions in the company. Envestnet Asset Management Inc. acquired a new position in shares of Cara Therapeutics in the first quarter worth approximately $256,000. Bank of New York Mellon Corp increased its holdings in Cara Therapeutics by 0.7% in the first quarter. Bank of New York Mellon Corp now owns 439,181 shares of the biopharmaceutical company’s stock worth $5,337,000 after purchasing an additional 3,067 shares in the last quarter. Cambridge Investment Research Advisors Inc. increased its holdings in Cara Therapeutics by 14.1% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 20,132 shares of the biopharmaceutical company’s stock worth $245,000 after purchasing an additional 2,482 shares in the last quarter. Citigroup Inc. increased its holdings in Cara Therapeutics by 5.7% in the first quarter. Citigroup Inc. now owns 86,370 shares of the biopharmaceutical company’s stock worth $1,049,000 after purchasing an additional 4,654 shares in the last quarter. Finally, Natixis Advisors L.P. increased its holdings in Cara Therapeutics by 101.2% in the first quarter. Natixis Advisors L.P. now owns 37,972 shares of the biopharmaceutical company’s stock worth $461,000 after purchasing an additional 19,102 shares in the last quarter. 44.66% of the stock is owned by institutional investors and hedge funds.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.